MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • SARS-CoV-2 Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • SARS-CoV-2 Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
  •  
  • Uncategorized
  • AIVITA Biomedical Announces 96% Immune Response Against SARS-CoV-2 in Phase 2 Clinical Trial of a Personalized Vaccine
  • Previous
  • Next

AIVITA Biomedical Announces 96% Immune Response Against SARS-CoV-2 in Phase 2 Clinical Trial of a Personalized Vaccine

0 comments

About the Author

user

user

Related Posts

AIVITA Biomedical Appoints Dr. H. Christian Fibiger to its Board of Directors
AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote at Festival of Biologics
AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote At Vaccine World Asia Congress
AIVITA Biomedical CEO Dr. Hans Keirstead to Chair Keynote Panel and Deliver Talk at World Immunotherapy Congress Europe

More From This Category

AIVITA Biomedical Appoints Dr. H. Christian Fibiger to its Board of Directors
AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote at Festival of Biologics
AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote At Vaccine World Asia Congress
AIVITA Biomedical CEO Dr. Hans Keirstead to Chair Keynote Panel and Deliver Talk at World Immunotherapy Congress Europe
  • Previous
  • Next

Recent Posts

  • AIVITA Biomedical Appoints Dr. H. Christian Fibiger to its Board of Directors
  • AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote at Festival of Biologics
  • AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote At Vaccine World Asia Congress
  • AIVITA Biomedical CEO Dr. Hans Keirstead to Chair Keynote Panel and Deliver Talk at World Immunotherapy Congress Europe
  • AIVITA Biomedical’s Stem Cell-Derived Retina Transplant Restores Vision Loss in Preclinical Study

Recent Comments

    Archives

    • April 2022
    • March 2022
    • November 2021
    • October 2021
    • September 2021
    • July 2021
    • June 2021
    • December 2020
    • November 2020
    • August 2020
    • July 2020
    • April 2020
    • February 2020
    • January 2020
    • November 2019
    • October 2019
    • September 2019
    • August 2019
    • July 2019
    • June 2019
    • May 2019
    • April 2019
    • March 2019
    • February 2019
    • January 2019
    • December 2018
    • November 2018
    • October 2018
    • September 2018
    • August 2018
    • July 2018
    • June 2018
    • May 2018
    • April 2018
    • March 2018
    • February 2018
    • December 2017
    • November 2017
    • September 2017
    • June 2017
    • May 2017
    • April 2017
    • February 2017
    • September 2016
    • July 2016
    • June 2016

    Categories

    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    AIVITA Biomedical is a biotechnology company developing personalized vaccines that target COVID-19 and the seed of all cancers using our autologous cell platform. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development in cancer, infectious disease and other fields.

    Recent News

    • AIVITA Biomedical Appoints Dr. H. Christian Fibiger to its Board of Directors
    • AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote at Festival of Biologics
    • AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote At Vaccine World Asia Congress
    • AIVITA Biomedical CEO Dr. Hans Keirstead to Chair Keynote Panel and Deliver Talk at World Immunotherapy Congress Europe
    • AIVITA Biomedical’s Stem Cell-Derived Retina Transplant Restores Vision Loss in Preclinical Study

    Site Navigation

    • About Us
    • Programs
    • News & Media
    • Contact Us
    Copyright © 2020 | AIVITA Biomedical, Inc.